Document is current

Article History

Accepted: 5 October 2022

First Online: 15 November 2022

Competing interests

: C.B. works in an institution that receives financial support from Abbvie, Amgen, AstraZeneca, Aveo Oncology, Bristol Myers Squibb, Celgene, Checkpoint Therapeutics, Daiichi, Docs, Exelixis, GSK, Henlius, ICON, IQVIA, Janssen, Labcorp, Lilly, Medpace, Merck Serono, Merck Sharp & Dohme, Myovant, Nektar, Novartis, Novocure, Nuvisan, OBI Pharma, Parexel, Pfizer, Pharmamar, Polyphor, Pharmaceutical Product Development, PSI, Regeneron, Roche, Sankyo, Sanofi, Seagen, Shanghai, Syneos Health, Takeda and TRIO; has received honoraria for advisory and/or consulting roles from AstraZeneca, Boehringer–Ingelheim, Bayer, Eisai, GSK, Lilly, Novartis, Pfizer, Roche–Genentech, Sanofi and Zodiac; and owns stock in MEDSir and Tummi. G.dL.L. works in an institution that receives or has received research funding from Abbvie, Adaptimmune, AstraZeneca, Bavarian Nordic, Blueprint Medicines, Bristol Myers Squibb, EMD Serono, G1 Therapeutics, GSK, Janssen, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche–Genentech and Tesaro; receives research funding from AstraZeneca, E.R. Squibb & Sons, Lucense and Xilis; has received honoraria for advisory and other roles from AstraZeneca, Blueprint Medicines, Boehringer–Ingelheim, Blueprint Medicines, Janssen, Merck and Pfizer; and owns stock in Lucence Diagnostics and Xilis. M.M.Y. has received honoraria for lectures, advisory roles and/or travel from Amgen, Astella, AstraZeneca, Bayer, Boehringer–Ingelheim, Celgene, DKSH, Eisai, Eli Lilly, Janssen, Merck Sharp & Dohme, Pfizer, Roche, Sanofi and Zuellig Pharma. P.R. has received honoraria for lectures and/or advisory roles from AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Merck, Merck Sharp & Dohme, Novartis, Philogen, Pierre Fabre and Sanofi, all outside the scope of this manuscript. F.R. and M.S. declare no competing interests.